Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer - Paridaens, R; Dirix, L; Lohrisch, C (Annals of oncology: official journal of the European Society for Medical Oncology/ESMO, 2003)
et al.